质子帮浦阻断剂的市场规模、份额和成长分析（按药物类型、给药途径、剂型、处方药、适应症和地区）：产业预测（2024-2031）

2022 年质子帮浦阻断剂的全球市场规模约为 46.5 亿美元，高于 2023 年的 49 亿美元，预测期内（2024-2031 年）和 2031 年的复合年增长率为 5.2%。亿。

质子帮浦阻断剂（PPI）是製药业的重要组成部分，主要用于治疗胃肠道疾病，如消化性溃疡、柔林格症候群和胃食道逆流（GERD）。这些药物透过抑制胃内壁的质子帮浦来发挥作用，有效降低胃酸水平。全球酸相关疾病的激增正在推动对非处方 (OTC) PPI 的需求，这种趋势以及药物配方的不断进步正在推动人口老化，而这往往需要此类治疗。然而，市场面临一些挑战，例如由于专利到期、监管障碍以及对长期使用质子帮浦抑制剂相关的长期副作用的担忧而导致学名药的竞争加剧。儘管存在这些障碍，市场仍然充满机会，特别是配方创新、数位健康技术的整合以及消费者对自我治疗的偏好不断增加。这些动态表明，PPI 在应对日益增长的健康挑战、同时适应不断变化的消费者偏好和医疗保健服务系统方面具有巨大潜力。总体而言，虽然市场正在克服某些挑战，但对有效胃肠道治疗的持续需求支撑了市场的弹性和对未来成长的预期。

目录

介绍

• 分析目的
• 定义
• 市场范围

分析方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 创新矩阵
• 主要投资机会
• 市场生态系统
• 价值链分析
• 技术分析
• 监管分析
• 临床试验分析
• 客户和购买标准分析

质子帮浦阻断剂市场：依药物类型

• 市场概况
• Esomeprazole
• 奥美拉唑
• 地克兰索拉唑
• 泮托拉唑
• Rabeprazole
• 兰索拉唑
• 其他的

质子帮浦阻断剂市场：依给药途径

• 市场概况
• 口服
• 注射

质子帮浦阻断剂市场：按剂型

• 市场概况
• 锭剂
• 胶囊
• 注射药物
• 其他的

质子帮浦阻断剂市场：依处方药分类

• 市场概况
• 品牌
• 非专利的

质子帮浦阻断剂市场：依迹象分类

• 市场概况
• 胃食道逆流症
• 胃灼热
• 消化性溃疡
• 其他的

质子帮浦阻断剂市场：按分销管道

• 市场概况
• 医院药房
• 零售药房
• 药局/诊所
• 其他的

质子帮浦阻断剂市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• 阿斯特捷利康（英国）
• 辉瑞公司（美国）
• 武田製药公司（日本）
• 拜耳公司（德国）
• 葛兰素史克公司（英国）
• 雷迪博士实验室有限公司（印度）
• 梯瓦製药工业股份有限公司（以色列）
• 太阳製药工业有限公司（印度）
• 赛诺菲公司（法国）
• Pharma Dynamics (Pty) Ltd.（南非）
• 艾伯维公司（美国）
• 羽扇豆有限公司（印度）
• 卫材株式会社（日本）
• 卡迪拉医疗保健有限公司 (Zydus Cadila)（印度）
• 西普拉有限公司（印度）
• 默克公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Torrent 製药有限公司（印度）
• RedHill Biopharma Ltd.（以色列）
• 住友大日本製药有限公司（日本）

Global Proton Pump Inhibitors Market size was valued at around USD 4.65 billion in 2022 and is expected to rise from USD 4.90 billion in 2023 to reach a value of USD 7.35 billion by 2031, at a CAGR of 5.2% over the forecast period (2024-2031).

Proton pump inhibitors (PPIs) represent a significant segment within the pharmaceutical industry, primarily addressing gastrointestinal disorders like peptic ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD). These medications function by inhibiting proton pumps in the stomach lining, effectively reducing stomach acid levels. The global surge in acid-related conditions is propelling the demand for over-the-counter (OTC) PPIs, a trend further intensified by an aging population that often requires such treatments, alongside continuous advancements in drug formulations. However, the market faces challenges from the expiration of patents, which has led to heightened competition from generic alternatives, as well as regulatory hurdles and concerns regarding the long-term side effects associated with prolonged PPI usage. Despite these obstacles, opportunities abound in the market, particularly through innovations in drug formulations, the integration of digital health technologies, and a growing consumer inclination towards self-medication. These dynamics indicate a robust potential for PPIs in addressing rising health challenges while adapting to the evolving landscape of consumer preferences and healthcare delivery systems. Overall, while the market navigates certain challenges, the continual demand for effective gastrointestinal treatments underscores its resilience and promise for future growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Proton Pump Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Proton Pump Inhibitors Market Segmental Analysis

Global Proton Pump Inhibitors Market is segmented by Drug Type, Route of Administration, Dosage Form, Prescription, Indication, Distribution Channel and region. Based on Drug Type, the market is segmented into Esomeprazole, Omeprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Lansoprazole, and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Dosage Form, the market is segmented into Tablet, Capsules, Injection, and Others. Based on Prescription, the market is segmented into Branded, and Generics. Based on Indication, the market is segmented into Gastroesophageal Reflux Disease, Heartburn, Peptic ulcers, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market is being significantly driven by the emergence of innovative formulations and delivery systems that enhance the therapeutic efficacy and safety profiles of these medications. The introduction of extended-release PPIs allows for improved patient compliance and more effective management of acid-related disorders. Furthermore, the development of combination therapies, where PPIs are synergistically used with other therapeutic agents, caters to the treatment of complex gastrointestinal conditions, thereby expanding their clinical applicability. This modernization in drug development not only meets evolving patient needs but also fosters a competitive landscape, propelling the overall market growth of PPIs.

Restraints in the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market faces significant restraints due to the adverse health effects associated with prolonged use of these medications. Risks such as increased chances of bone fractures, kidney disease, and deficiencies in crucial vitamins like magnesium and B12 are prompting healthcare professionals to exercise greater caution in prescribing PPIs. This heightened vigilance may lead to reduced prescription rates, ultimately suppressing market growth. Additionally, the potential for long-term PPI use to contribute to Clostridium difficile infections poses further challenges, complicating treatment protocols and negatively impacting patient outcomes, thereby affecting the overall demand for these products in the healthcare industry.

Market Trends of the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market is experiencing a notable trend towards the introduction of alternatives and innovative formulations designed to improve treatment outcomes while minimizing side effects. Researchers are actively developing novel delivery systems, including combination therapies and delayed-release formulations to enhance efficacy. Concurrently, there's a burgeoning interest in alternative therapies such as prokinetic agents and H2-receptor antagonists, alongside dietary modifications to manage acid-related disorders more effectively. This shift not only reflects the growing demand for personalized medicine but also addresses concerns regarding long-term PPI use, ultimately reshaping the landscape of acid suppression treatments.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Innovation Matrix
• Top Investment Pockets
• Ecosystem of the Market
• Value Chain Analysis
• Technology Analysis
• Regulatory Analysis
• Clinical trials Analysis
• Customer & Buying Criteria Analysis

Proton Pump Inhibitors Market, By Drug Type

• Market Overview
• Esomeprazole
• Omeprazole
• Dexlansoprazole
• Pantoprazole
• Rabeprazole
• Lansoprazole
• Others

Proton Pump Inhibitors Market, By Route of Administration

• Market Overview
• Oral
• Injectable

Proton Pump Inhibitors Market, By Dosage Form

• Market Overview
• Tablet
• Capsules
• Injection
• Others

Proton Pump Inhibitors Market, By Prescription

• Market Overview
• Branded
• Generics

Proton Pump Inhibitors Market, By Indication

• Market Overview
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic ulcers
• Others

Proton Pump Inhibitors Market, By Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores and Clinics
• Others

Proton Pump Inhibitors Market, by region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharma Dynamics (Pty) Ltd. (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare Ltd. (Zydus Cadila) (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RedHill Biopharma Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments